The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Open accessAbstract
BACKGROUND: Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer. METHODS: We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients). The primary end point was progression-free survival. The mutation status of the KRAS gene was evaluated as a predictor of outcome. RESULTS: The median progression-free survival was 10.7 months in the CB group and 9.4 in the CBC group (P=0.01). Quality-of-life scores were lower in the CBC group. The overall survival and response rates did not differ significantly in the two groups. Treated patients in the CBC group had more grade 3 or 4 adverse events, which were attributed to cetuximab-related adverse cutaneous effects. Patients treated with cetuximab who had tumors bearing a mutated KRAS gene had significantly decreased progression-free survival as compared with cetuximab-treated patients with wild-type-KRAS tumors or patients with mutated-KRAS tumors in the CB group. CONCLUSIONS: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life. Mutation status of the KRAS gene was a predictor of outcome in the cetuximab group. (ClinicalTrials.gov number, NCT00208546.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Kabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 630
Self-citationSeymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., Smith, D. B., Shepherd, S., Maraveyas, A., Ferry, D. R., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61087-3 · Cited by 561
Saltz, L. B., Lenz, H.-J., Kindler, H. L., Hochster, H. S., Wadler, S., Hoff, P. M., Kemeny, N. E., Hollywood, E. M., Gonen, M., Quinones, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0949 · Cited by 425
Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., Placido, S. D., Bianco, A. R., Mendelsohn, J. M., & Tortora, G. (2000) · PubMed · Cited by 378
Van Cutsem, E., Lang, I., D'haens, G., Moiseyenko, V., Zaluski, J., Folprecht, G., Tejpar, S., Kisker, O., Stroh, C., & Rougier, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2 · Cited by 372
Scartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., & Cascinu, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn637 · Cited by 327
Porschen, R., Arkenau, H.-T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., Kretzschmar, A., Graeven, U., Grothey, A., Hinke, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2684 · Cited by 280
Díaz-Rubio, E., Tabernero, J., Gómez-España, A., Massutí, B., Sastre, J., Chaves, M., Abad, A., Carrato, A., Queralt, B., Reina, J. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8467 · Cited by 268
Jung, Y. D., Mansfield, P. F., Akagi, M., Takeda, A., Liu, W., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00013-8 · Cited by 249
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., De Braud, F. G., Volovat, C., Nippgen, J., Stroh, C., Celik, I., & Koralewski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4000 · Cited by 240
Shaheen, R. M., Ahmad, S. A., Liu, W., Reinmuth, N., Jung, Y. D., Tseng, W. W., Drazan, K. E., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1936 · Cited by 235
Tol, J., Koopman, M., Rodenburg, C. J., Cats, A., Creemers, G. J., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., Mol, L., Antonini, N. F., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm607 · Cited by 212
Self-citationTonra, J. R., Deevi, D. S., Corcoran, E., Li, H., Wang, S., Carrick, F. E., & Hicklin, D. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1682 · Cited by 151
Shanafelt, T. D., Hanson, C. A., Dewald, G. W., Witzig, T. E., LaPlant, B. R., Abrahamzon, J. L., Jelinek, D. F., & Kay, N. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7874 · Cited by 72
Bleomycin in Testicular Cancer: Will Pharmacogenomics Improve Treatment Regimens?
Bokemeyer, C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2991 · Cited by 46
Bokemeyer, C., Starosławska, E., Makhson, A. M., Bondarenko, I., Hartmann, J. T., Shelygin, Y., Колеснік, О. П., Volovat, C. D., Zubel, A., & Koralewski, P. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70932-1 · Cited by 27
Cited by
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Metadata
- Authors
- Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., Richel, D. J., Voest, E. E., Dijkstra, J. R., Vink-Börger, M. E., Antonini, N. F., Mol, L., van Krieken, J. H. J. M., Dalesio, O., & Punt, C. J. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-02-05
- Volume
- 360
- Issue
- 6
- Pages
- 563-572
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127640925
- Cited by
- 1,341
- References
- 26
- FWCI
- 83.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.